News
Mycenax Biotech and Spera Pharma collaborate to streamline ADC drug substance and drug product manufacturing services: Taiwan Tuesday, September 16, 2025, 16:00 Hrs [IST] Mycenax ...
Avanos Medical acquires Nexus Medical to strengthen nutrition and medication delivery in critical care: Alpharetta, Georgia Tuesday, September 16, 2025, 14:00 Hrs [IST] Avanos Med ...
Waltham, Massachusetts Tuesday, September 16, 2025, 18:00 Hrs [IST] ...
Malvern, Pennsylvania Tuesday, September 16, 2025, 11:00 Hrs [IST] ...
Apollo Hospitals announce major acquisition and new oncology centre: Our Bureau, Chennai Tuesday, September 16, 2025, 17:15 Hrs [IST] Apollo Hospitals Enterprise Ltd (AHEL) has ma ...
US FDA grants breakthrough therapy designation to Daiichi Sankyo & Merck’s raludotatug deruxtecan for patients with CDH6 expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube ...
Abzena enhances AbZelectPRO cell line offering with new GS knockout platforms: San Diego, California Tuesday, September 16, 2025, 13:00 Hrs [IST] Abzena, the leading end-to-end in ...
Molbio Diagnostics collaborates with UE LifeSciences to expand iBreastExam to the global market: Our Bureau, Mumbai Tuesday, September 16, 2025, 16:15 Hrs [IST] Molbio Diagnostics ...
Japan’s MHLW approves Novocure’s Optune Lua to treat unresectable advanced/recurrent non-small cell lung cancer: Baar, Switzerland Tuesday, September 16, 2025, 17:00 Hrs [IST] ...
Avita Medical, Inc., a leading therapeutic acute wound care company, announced it has received the CE Mark under the European Union Medical Device Regulation (EU MDR) for RECELL GO. This allows the ...
Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukaemias: Barcelona, Spain Tuesday, September 16, 202 ...
CollPlant Biotechnologies expands the distribution of its VergenixSTR product in Europe: Rehovot, Israel Tuesday, September 16, 2025, 15:00 Hrs [IST] CollPlant Biotechnologies, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results